XML 46 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Fair Value - Additional Information (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2024
USD ($)
Jul. 31, 2023
USD ($)
Installment
Apr. 07, 2022
Oct. 31, 2024
USD ($)
Jul. 31, 2024
USD ($)
Apr. 30, 2024
USD ($)
Installment
Apr. 30, 2022
USD ($)
Installment
Jan. 31, 2016
USD ($)
shares
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2018
USD ($)
Installment
shares
Feb. 28, 2025
$ / shares
Nov. 21, 2022
shares
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Change in fair value of warrant liability                 $ 378        
IPO                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Warrant, exercise price | $ / shares                   $ 4.46      
2018 Notes | Series G Preferred Stock                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Warrant issued to purchase shares | shares                   613,333      
Warrant, exercise price | $ / shares                   $ 0.75      
Contingent Consideration                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Interest expense due to passage of time and fixed payment schedule                   $ 700      
Contingent Consideration | Third Amendment to APA Agreement                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Milestone payment         $ 8,400                
Warrant Liabilities                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Warrant issued to purchase shares | shares                         5,000,000
Change in fair value of warrant liability                 400 0      
Warrant Liabilities | Tranche C Loan                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Warrant, exercise price | $ / shares                       $ 0.793  
Contingent Value Rights | Series F Preferred Stock                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Change in fair value of warrant liability                 $ 0 $ 0      
Percentage of net proceeds               15.00%          
Contingent Value Rights | Series F Preferred Stock | Ficlatuzumab                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Contingent value rights interest rate               0.00375%          
Shares issued | shares               3,999          
Drug interest rate percentage               15.00%          
Contingent value rights               $ 500          
Integrated Diagnostics, Inc                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Exit fee payment $ 6,100                        
Integrated Diagnostics, Inc | Contingent Consideration                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Business acquisition description                 required additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month        
Business acquisition contingent consideration gross margin target                     $ 2,000    
Business acquisition contingent consideration gross margin target period                     7 years    
Integrated Diagnostics, Inc | Contingent Consideration | Third Amendment to APA Agreement                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Contingent consideration number of installments | Installment   3       1 5            
Milestone payment   $ 3,000       $ 5,000 $ 2,000            
Percentage of interest on installment payments     10.00%                    
Exit fee payment       $ 6,100                  
Integrated Diagnostics, Inc | Common Stock | Contingent Consideration                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Business acquisition description                 If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.        
Contingent consideration shares | shares                     2,520,108    
Contingent consideration number of installments | Installment                     8    
Contingent consideration arrangements, common shares, redemption amount                 $ 4,600   $ 37,000    
Repayments of debt                 9,300        
Business combination contingent consideration final payment                 $ 37,000        
Contingent consideration cash payment                     $ 37,000    
Investment, Type [Extensible Enumeration]                     Repurchase [Member]